Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the...
The money--which follows a $70 million round two years ago--will be used to put RLY5016 to the ultimate test as a treatment for hyperkalemia, a condition in which high levels of potassium threatens patients suffering from diabetes, heart failure, and kidney disease with a potentially lethal case of arrhythmia.
Two years after an experienced team of biotech executives gathered a whopping $70 million venture round for Relypsa, the Santa Clara, CA-based developer is almost $50 million closer to another big round of financing, according to SEC documents.
Relypsa, the start-up biotech born out of Amgen's acquisition of Ilypsa, has rounded up a whopping $70 million for its Series B, bringing its venture haul to more than $100 million. Santa Clara,